DelfaGLP-1 Atlas

Lead sponsor

GlaxoSmithKline

39 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

39

Trials led

0

Active

18,085

Total enrollment

1,262

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
11
Phase 2
7
Phase 3
14
Phase 4
5
Not applicable
2

Trials by status

Completed
34
Terminated
3
Withdrawn
2

Trials led

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusEstablished CVDPh 4Completed9,463
Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesBMI 20-45Ph 3Completed1,049
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.HbA1c 7-10%Ph 3Completed841
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes MellitusBMI ≤40Ph 3Completed814
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesBMI 20-45Ph 3Completed779
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 DiabetesBMI 20-45Ph 3Completed685
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineHbA1c ≤7%Ph 3Completed586
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.HbA1c 7-10%Ph 3Completed507
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)BMI 17-40Ph 3Completed494
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes MellitusBMI 17-40Ph 3Completed374
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin OnlyBMI 20-40Ph 2Completed361
Safety and Efficacy of Albiglutide in Type 2 DiabetesBMI 20-45Ph 3Completed310
Safety and Efficacy Study of Albiglutide in Type 2 DiabetesBMI 20-45Ph 3Completed309
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes MellitusBMI ≤40Ph 3Completed308
Pharmacokinetics/Pharmacodynamics of AlbiglutideBMI 20-45Ph 2Completed283
Dose Ranging Study of Albiglutide in Japanese SubjectsBMI 18-35Ph 2Completed215
Albiglutide Thorough ECG Study in Healthy VolunteersBMI 18-30Ph 1Completed94
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.HbA1c 6-10.5%Ph 1Completed75
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes MellitusBMI ≤32Ph 2Completed67
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus—Ph 2Completed60
Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult SubjectsBMI ≥18Ph 1Completed59
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 DiabetesBMI 18-35Ph 2Completed53
Albiglutide Glucose Clamp Study in Subjects With Type 2 DiabetesBMI 28-40Ph 2Completed44
Clinical Assessment of GSK716155 for Type 2 Diabetes MellitusBMI 20-70Ph 1Completed40
A Drug Interaction Study of Simvastatin and AlbiglutideBMI ≤30Ph 1Completed40
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.BMI 20-32Ph 1Completed34
A Drug Interaction Study of Albiglutide and DigoxinBMI ≤30Ph 1Completed30
In-patient Study in Patients With Type 2 Diabetes Mellitus—Ph 1Completed30
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy SubjectsBMI 2-30Ph 4Completed20
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .BMI 19-30Ph 1Completed16
A Drug Interaction Study With Albiglutide and WarfarinBMI ≤30Ph 1Completed16
Feasibility Study of Exenatide by Continuous Subcutaneous InfusionHealthy volunteersPh 1Completed10
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects—Ph 4Terminated8
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy SubjectsHealthy volunteersPh 4Terminated5
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus SubjectsBMI 2-35Ph 4Terminated4
Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine—not applicableCompleted1
Glucagon-like Peptide (GLP) Utilization and Safety—not applicableCompleted1
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes MellitusBMI ≤40Ph 3Withdrawnnot disclosed
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes MellitusHbA1c ≤10%Ph 3Withdrawnnot disclosed